RET重排非小细胞肺癌的分子特征与临床结局
该回顾性研究纳入新加坡国家癌症中心64例RET重排NSCLC患者,比较FISH与NGS检测一致性及系统治疗结局。选择性RET酪氨酸激酶抑制剂较未治疗显著延长总生存(中位49.3 vs 15.3个月,HR 0.16),免疫治疗无生存获益,CCDC6-RET融合患者生存优于KIF5B-RET。
要点
- 选择性RET酪氨酸激酶抑制剂显著改善RET重排NSCLC总生存。
- 免疫治疗在RET重排NSCLC中未显示生存获益。
- CCDC6-RET融合患者生存优于KIF5B-RET融合患者。
核心结论
- 在RET重排NSCLC中,选择性RET酪氨酸激酶抑制剂治疗与改善生存相关,尤其CCDC6-RET融合患者,而免疫治疗疗效差。
研究设计与样本
- 本研究为新加坡国家癌症中心治疗的RET重排NSCLC患者的回顾性分析,共纳入64例患者。
主要发现
- 64例患者中位年龄62岁(范围25-85),56%为女性,77%为华裔,95%为腺癌,69%为从不吸烟者。
- FISH检测RET重排在30/34例(88%)中阳性,NGS在40/43例(93%)中阳性,双方法检测的13例中7例(54%)结果不一致。
- 61例IIIB/IV期或复发患者中,中枢神经系统转移患病率为31%,92%接受了姑息性系统治疗。
- 选择性RET酪氨酸激酶抑制剂治疗者较未治疗者总生存延长(中位49.3 vs 15.3个月;HR 0.16,95%CI 0.06-0.40,p<0.001)。
- 免疫治疗者与未治疗者总生存无差异(中位37.7 vs 49.3个月;HR 1.30,95%CI 0.53-3.19,p=0.53)。
临床怎么用
- 对RET重排NSCLC患者,优先考虑选择性RET酪氨酸激酶抑制剂治疗。
- 免疫治疗在RET重排NSCLC中疗效不佳,决策时需谨慎。
- 检测RET重排时需注意FISH与NGS方法间可能存在显著不一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: RET rearrangements are an emerging targetable oncogenic fusion driver in NSCLC. However, the natural history of disease and activity of different classes of systemic therapy remain to be defined. Furthermore, molecular testing for RET is not yet routine, and the optimal method of testing is unclear. We present a comparative analysis of molecular profiling with fluorescence in situ hybridization (FISH) or next-generation sequencing (NGS) and treatment outcomes. METHODS: This study was a retrospective analysis of patients treated at the National Cancer Centre Singapore. Baseline demographics and treatment outcomes were collected. RESULTS: A total of 64 patients were included, with a median age of 62 years (range: 25-85), 56% were women, 77% were of Chinese ethnicity, 95% had adenocarcinoma, and 69% were never smokers. RET rearrangement was detected by FISH in 30 of 34 patients (88%), NGS in 40 of 43 patients (93%), and with discordant results in seven of 13 patients (54%) tested with both methods. Of 61 patients with stage IIIB/IV or recurrent disease, prevalence of central nervous system metastases was 31% and 92% received palliative systemic therapy. Overall survival was prolonged in patients treated with a selective RET tyrosine kinase inhibitor versus untreated patients (median 49.3 versus 15.3 mo; hazard ratio [HR]: 0.16, 95% confidence interval [CI]: 0.06-0.40, p < 0.001). However, it was not different in patients treated with immunotherapy versus untreated patients (median 37.7 versus 49.3 mo; HR: 1.30, 95% CI: 0.53-3.19, p = 0.53). Overall survival was also prolonged in patients with CCDC6-RET fusion versus those with KIF5B-RET fusion (median 113.5 versus 37.7 mo; HR: 0.12, 95% CI: 0.04-0.38, p = 0.009). CONCLUSIONS: In RET-rearranged NSCLC, selective RET tyrosine kinase inhibitor therapy is associated with improved survival outcomes, especially in patients with CCDC6-RET fusion. However, immunotherapy has poor efficacy. NGS and FISH testing methods may also result in substantial discordance.
引用
- Tan AC, Seet AOL, Lai GGY, et al. Molecular Characterization and Clinical Outcomes in RET-Rearranged NSCLC. J Thorac Oncol. 2020. PMID: 32866654. doi:10.1016/j.jtho.2020.08.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。